nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—CYP3A4—Pilocarpine—glaucoma	0.0614	0.236	CbGbCtD
Fulvestrant—CYP3A4—Brinzolamide—glaucoma	0.0482	0.185	CbGbCtD
Fulvestrant—CYP3A4—Dorzolamide—glaucoma	0.0466	0.178	CbGbCtD
Fulvestrant—CYP3A4—Methazolamide—glaucoma	0.0415	0.159	CbGbCtD
Fulvestrant—CYP3A4—Acetazolamide—glaucoma	0.0332	0.127	CbGbCtD
Fulvestrant—CYP3A4—Clonidine—glaucoma	0.03	0.115	CbGbCtD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—POU4F1—glaucoma	0.00475	0.0253	CbGpPWpGaD
Fulvestrant—NR1H4—Endogenous sterols—CYP1B1—glaucoma	0.00439	0.0233	CbGpPWpGaD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—POU4F2—glaucoma	0.00437	0.0232	CbGpPWpGaD
Fulvestrant—EPHX2—Arachidonic acid metabolism—CYP1B1—glaucoma	0.00404	0.0215	CbGpPWpGaD
Fulvestrant—NR1H4—RXR and RAR heterodimerization with other nuclear receptor—ABCA1—glaucoma	0.00398	0.0212	CbGpPWpGaD
Fulvestrant—ESR2—Validated nuclear estrogen receptor beta network—C3—glaucoma	0.0038	0.0202	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—LMX1B—glaucoma	0.00361	0.0192	CbGpPWpGaD
Fulvestrant—NR1H4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.00321	0.0171	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—PITX2—glaucoma	0.00307	0.0163	CbGpPWpGaD
Fulvestrant—ESR1—Estrogen Receptor Pathway—CYP1B1—glaucoma	0.00304	0.0162	CbGpPWpGaD
Fulvestrant—ESRRA—Nuclear Receptors—NR3C1—glaucoma	0.00297	0.0158	CbGpPWpGaD
Fulvestrant—Estradiol—CYP1B1—glaucoma	0.00282	1	CrCbGaD
Fulvestrant—ESR2—Ovarian Infertility Genes—CCND2—glaucoma	0.00276	0.0147	CbGpPWpGaD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—POU4F1—glaucoma	0.0024	0.0127	CbGpPWpGaD
Fulvestrant—ESRRA—Nuclear Receptor transcription pathway—NR3C1—glaucoma	0.00235	0.0125	CbGpPWpGaD
Fulvestrant—ESR1—LKB1 signaling events—RPTOR—glaucoma	0.00222	0.0118	CbGpPWpGaD
Fulvestrant—NR1H4—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.00204	0.0108	CbGpPWpGaD
Fulvestrant—ESR1—Signaling events mediated by HDAC Class II—HDAC9—glaucoma	0.00202	0.0107	CbGpPWpGaD
Fulvestrant—ESR2—Nuclear Receptors—NR3C1—glaucoma	0.00189	0.0101	CbGpPWpGaD
Fulvestrant—EPHX2—Arachidonic acid metabolism—PTGS2—glaucoma	0.00182	0.00967	CbGpPWpGaD
Fulvestrant—ESRRA—PPARA activates gene expression—ABCA1—glaucoma	0.00172	0.00913	CbGpPWpGaD
Fulvestrant—NR1H4—Nuclear Receptor transcription pathway—NR3C1—glaucoma	0.00172	0.00913	CbGpPWpGaD
Fulvestrant—ESRRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—ABCA1—glaucoma	0.00168	0.00894	CbGpPWpGaD
Fulvestrant—NR1H4—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.00165	0.00878	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PITX2—glaucoma	0.00155	0.00824	CbGpPWpGaD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—SOD1—glaucoma	0.0015	0.00799	CbGpPWpGaD
Fulvestrant—ESR2—Nuclear Receptor transcription pathway—NR3C1—glaucoma	0.0015	0.00795	CbGpPWpGaD
Fulvestrant—EPHX2—Metapathway biotransformation—CYP1B1—glaucoma	0.00148	0.00788	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.0014	0.00746	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—PEX19—glaucoma	0.0014	0.00745	CbGpPWpGaD
Fulvestrant—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—glaucoma	0.00133	0.00708	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—NARFL—glaucoma	0.00132	0.00703	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—CA5A—glaucoma	0.00132	0.00703	CbGpPWpGaD
Fulvestrant—CYP3A4—Aflatoxin B1 metabolism—GSTM1—glaucoma	0.0013	0.00692	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—HDAC9—glaucoma	0.0013	0.00689	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—MMP2—glaucoma	0.00127	0.00673	CbGpPWpGaD
Fulvestrant—NR1H4—PPARA activates gene expression—ABCA1—glaucoma	0.00126	0.00667	CbGpPWpGaD
Fulvestrant—ESR2—Ovarian Infertility Genes—CDKN1B—glaucoma	0.00125	0.00666	CbGpPWpGaD
Fulvestrant—NR1H4—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—ABCA1—glaucoma	0.00123	0.00653	CbGpPWpGaD
Fulvestrant—NR1H4—RXR and RAR heterodimerization with other nuclear receptor—TNF—glaucoma	0.00121	0.00644	CbGpPWpGaD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—C3—glaucoma	0.00119	0.00633	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—NOS3—glaucoma	0.00119	0.00631	CbGpPWpGaD
Fulvestrant—EPHX2—Metapathway biotransformation—GSTM1—glaucoma	0.00118	0.0063	CbGpPWpGaD
Fulvestrant—ESRRA—Fatty acid, triacylglycerol, and ketone body metabolism—ABCA1—glaucoma	0.00116	0.00616	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.00112	0.00596	CbGpPWpGaD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—CYP1B1—glaucoma	0.00111	0.00589	CbGpPWpGaD
Fulvestrant—NR1H4—Biological oxidations—GSTT1—glaucoma	0.0011	0.00586	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—TGFB2—glaucoma	0.00107	0.00567	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CA5A—glaucoma	0.00106	0.00562	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—NARFL—glaucoma	0.00106	0.00562	CbGpPWpGaD
Fulvestrant—ESR1—FOXA1 transcription factor network—SOD1—glaucoma	0.00102	0.00544	CbGpPWpGaD
Fulvestrant—ESR1—Signaling events mediated by HDAC Class II—NR3C1—glaucoma	0.000954	0.00507	CbGpPWpGaD
Fulvestrant—ESR1—Nuclear Receptors—NR3C1—glaucoma	0.000954	0.00507	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—MMP9—glaucoma	0.000952	0.00506	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000947	0.00503	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—NTRK2—glaucoma	0.000927	0.00493	CbGpPWpGaD
Fulvestrant—NR1H4—Biological oxidations—CYP1B1—glaucoma	0.000878	0.00467	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	0.000862	0.00458	CbGpPWpGaD
Fulvestrant—NR1H4—Fatty acid, triacylglycerol, and ketone body metabolism—ABCA1—glaucoma	0.000846	0.0045	CbGpPWpGaD
Fulvestrant—Dermatitis—Latanoprost—glaucoma	0.000841	0.00153	CcSEcCtD
Fulvestrant—Dyspepsia—Acetazolamide—glaucoma	0.000841	0.00153	CcSEcCtD
Fulvestrant—Headache—Latanoprost—glaucoma	0.000836	0.00153	CcSEcCtD
Fulvestrant—Skin disorder—Brinzolamide—glaucoma	0.000836	0.00152	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Brimonidine—glaucoma	0.000835	0.00152	CcSEcCtD
Fulvestrant—Anorexia—Dorzolamide—glaucoma	0.000834	0.00152	CcSEcCtD
Fulvestrant—Decreased appetite—Acetazolamide—glaucoma	0.00083	0.00151	CcSEcCtD
Fulvestrant—Insomnia—Brimonidine—glaucoma	0.000829	0.00151	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000824	0.0015	CcSEcCtD
Fulvestrant—Fatigue—Acetazolamide—glaucoma	0.000823	0.0015	CcSEcCtD
Fulvestrant—Paraesthesia—Brimonidine—glaucoma	0.000823	0.0015	CcSEcCtD
Fulvestrant—Infection—Pilocarpine—glaucoma	0.000822	0.0015	CcSEcCtD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.00082	0.00436	CbGpPWpGaD
Fulvestrant—Nausea—Methazolamide—glaucoma	0.000819	0.00149	CcSEcCtD
Fulvestrant—Dyspnoea—Brimonidine—glaucoma	0.000817	0.00149	CcSEcCtD
Fulvestrant—Dyspepsia—Brimonidine—glaucoma	0.000807	0.00147	CcSEcCtD
Fulvestrant—Pharyngitis—Betaxolol—glaucoma	0.000803	0.00147	CcSEcCtD
Fulvestrant—Hyperhidrosis—Pilocarpine—glaucoma	0.000799	0.00146	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Dorzolamide—glaucoma	0.000797	0.00145	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Travoprost—glaucoma	0.000794	0.00145	CcSEcCtD
Fulvestrant—Insomnia—Dorzolamide—glaucoma	0.000792	0.00144	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Brimonidine—glaucoma	0.000791	0.00144	CcSEcCtD
Fulvestrant—Fatigue—Brimonidine—glaucoma	0.00079	0.00144	CcSEcCtD
Fulvestrant—Anorexia—Pilocarpine—glaucoma	0.000788	0.00144	CcSEcCtD
Fulvestrant—Hypersensitivity—Apraclonidine—glaucoma	0.000786	0.00143	CcSEcCtD
Fulvestrant—Paraesthesia—Dorzolamide—glaucoma	0.000786	0.00143	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Brinzolamide—glaucoma	0.000784	0.00143	CcSEcCtD
Fulvestrant—Pain—Brimonidine—glaucoma	0.000784	0.00143	CcSEcCtD
Fulvestrant—Dyspnoea—Dorzolamide—glaucoma	0.00078	0.00142	CcSEcCtD
Fulvestrant—Insomnia—Brinzolamide—glaucoma	0.000778	0.00142	CcSEcCtD
Fulvestrant—Dyspnoea—Travoprost—glaucoma	0.000777	0.00142	CcSEcCtD
Fulvestrant—Paraesthesia—Brinzolamide—glaucoma	0.000773	0.00141	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—NARFL—glaucoma	0.000772	0.0041	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CA5A—glaucoma	0.000772	0.0041	CbGpPWpGaD
Fulvestrant—Dyspepsia—Dorzolamide—glaucoma	0.00077	0.00141	CcSEcCtD
Fulvestrant—Dyspnoea—Brinzolamide—glaucoma	0.000767	0.0014	CcSEcCtD
Fulvestrant—Dyspepsia—Travoprost—glaucoma	0.000767	0.0014	CcSEcCtD
Fulvestrant—Asthenia—Apraclonidine—glaucoma	0.000766	0.0014	CcSEcCtD
Fulvestrant—CYP3A4—Estrogen metabolism—CYP1B1—glaucoma	0.000764	0.00406	CbGpPWpGaD
Fulvestrant—Decreased appetite—Dorzolamide—glaucoma	0.000761	0.00139	CcSEcCtD
Fulvestrant—Urticaria—Acetazolamide—glaucoma	0.000759	0.00138	CcSEcCtD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—SOD1—glaucoma	0.000758	0.00403	CbGpPWpGaD
Fulvestrant—Dyspepsia—Brinzolamide—glaucoma	0.000757	0.00138	CcSEcCtD
Fulvestrant—Pruritus—Apraclonidine—glaucoma	0.000755	0.00138	CcSEcCtD
Fulvestrant—Body temperature increased—Acetazolamide—glaucoma	0.000755	0.00138	CcSEcCtD
Fulvestrant—Fatigue—Dorzolamide—glaucoma	0.000755	0.00138	CcSEcCtD
Fulvestrant—ESR1—Nuclear Receptor transcription pathway—NR3C1—glaucoma	0.000754	0.00401	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Pilocarpine—glaucoma	0.000753	0.00137	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Travoprost—glaucoma	0.000752	0.00137	CcSEcCtD
Fulvestrant—Fatigue—Travoprost—glaucoma	0.000751	0.00137	CcSEcCtD
Fulvestrant—Pain—Dorzolamide—glaucoma	0.000748	0.00137	CcSEcCtD
Fulvestrant—Insomnia—Pilocarpine—glaucoma	0.000748	0.00136	CcSEcCtD
Fulvestrant—Decreased appetite—Brinzolamide—glaucoma	0.000748	0.00136	CcSEcCtD
Fulvestrant—Pain—Travoprost—glaucoma	0.000745	0.00136	CcSEcCtD
Fulvestrant—Constipation—Travoprost—glaucoma	0.000745	0.00136	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000743	0.00135	CcSEcCtD
Fulvestrant—Paraesthesia—Pilocarpine—glaucoma	0.000743	0.00135	CcSEcCtD
Fulvestrant—Asthenia—Bimatoprost—glaucoma	0.000743	0.00135	CcSEcCtD
Fulvestrant—Fatigue—Brinzolamide—glaucoma	0.000742	0.00135	CcSEcCtD
Fulvestrant—Angioedema—Clonidine—glaucoma	0.000739	0.00135	CcSEcCtD
Fulvestrant—Dyspnoea—Pilocarpine—glaucoma	0.000737	0.00134	CcSEcCtD
Fulvestrant—Pain—Brinzolamide—glaucoma	0.000736	0.00134	CcSEcCtD
Fulvestrant—Depression—Timolol—glaucoma	0.000734	0.00134	CcSEcCtD
Fulvestrant—Angiopathy—Betaxolol—glaucoma	0.000734	0.00134	CcSEcCtD
Fulvestrant—Pruritus—Bimatoprost—glaucoma	0.000732	0.00134	CcSEcCtD
Fulvestrant—Immune system disorder—Betaxolol—glaucoma	0.000731	0.00133	CcSEcCtD
Fulvestrant—Diarrhoea—Apraclonidine—glaucoma	0.00073	0.00133	CcSEcCtD
Fulvestrant—Dyspepsia—Pilocarpine—glaucoma	0.000728	0.00133	CcSEcCtD
Fulvestrant—Decreased appetite—Pilocarpine—glaucoma	0.000719	0.00131	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Dorzolamide—glaucoma	0.000716	0.00131	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000714	0.0013	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Travoprost—glaucoma	0.000713	0.0013	CcSEcCtD
Fulvestrant—Pain—Pilocarpine—glaucoma	0.000707	0.00129	CcSEcCtD
Fulvestrant—Constipation—Pilocarpine—glaucoma	0.000707	0.00129	CcSEcCtD
Fulvestrant—Cough—Clonidine—glaucoma	0.000706	0.00129	CcSEcCtD
Fulvestrant—Sweating—Timolol—glaucoma	0.000706	0.00129	CcSEcCtD
Fulvestrant—Dizziness—Apraclonidine—glaucoma	0.000706	0.00129	CcSEcCtD
Fulvestrant—Malnutrition—Betaxolol—glaucoma	0.000704	0.00129	CcSEcCtD
Fulvestrant—NR1H4—Biological oxidations—GSTM1—glaucoma	0.000702	0.00373	CbGpPWpGaD
Fulvestrant—Urticaria—Dorzolamide—glaucoma	0.000695	0.00127	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—BDNF—glaucoma	0.000692	0.00368	CbGpPWpGaD
Fulvestrant—Abdominal pain—Dorzolamide—glaucoma	0.000692	0.00126	CcSEcCtD
Fulvestrant—Body temperature increased—Dorzolamide—glaucoma	0.000692	0.00126	CcSEcCtD
Fulvestrant—Arthralgia—Clonidine—glaucoma	0.000689	0.00126	CcSEcCtD
Fulvestrant—Chest pain—Clonidine—glaucoma	0.000689	0.00126	CcSEcCtD
Fulvestrant—Abdominal pain—Travoprost—glaucoma	0.000689	0.00126	CcSEcCtD
Fulvestrant—Anxiety—Clonidine—glaucoma	0.000687	0.00125	CcSEcCtD
Fulvestrant—Asthenia—Acetazolamide—glaucoma	0.000685	0.00125	CcSEcCtD
Fulvestrant—Dizziness—Bimatoprost—glaucoma	0.000684	0.00125	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000684	0.00125	CcSEcCtD
Fulvestrant—Urticaria—Brinzolamide—glaucoma	0.000684	0.00125	CcSEcCtD
Fulvestrant—Vomiting—Apraclonidine—glaucoma	0.000679	0.00124	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Pilocarpine—glaucoma	0.000676	0.00123	CcSEcCtD
Fulvestrant—CYP3A4—Tamoxifen metabolism—CYP1B1—glaucoma	0.000676	0.00359	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Brimonidine—glaucoma	0.000675	0.00123	CcSEcCtD
Fulvestrant—Dermatitis—Apraclonidine—glaucoma	0.000672	0.00123	CcSEcCtD
Fulvestrant—Headache—Apraclonidine—glaucoma	0.000669	0.00122	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—IL1A—glaucoma	0.000665	0.00353	CbGpPWpGaD
Fulvestrant—Asthenia—Brimonidine—glaucoma	0.000658	0.0012	CcSEcCtD
Fulvestrant—Infection—Clonidine—glaucoma	0.000656	0.0012	CcSEcCtD
Fulvestrant—Body temperature increased—Pilocarpine—glaucoma	0.000654	0.00119	CcSEcCtD
Fulvestrant—Abdominal pain—Pilocarpine—glaucoma	0.000654	0.00119	CcSEcCtD
Fulvestrant—Diarrhoea—Acetazolamide—glaucoma	0.000653	0.00119	CcSEcCtD
Fulvestrant—Rash—Bimatoprost—glaucoma	0.000653	0.00119	CcSEcCtD
Fulvestrant—Dermatitis—Bimatoprost—glaucoma	0.000652	0.00119	CcSEcCtD
Fulvestrant—Oedema peripheral—Timolol—glaucoma	0.000651	0.00119	CcSEcCtD
Fulvestrant—Anaemia—Betaxolol—glaucoma	0.000651	0.00119	CcSEcCtD
Fulvestrant—Connective tissue disorder—Timolol—glaucoma	0.00065	0.00119	CcSEcCtD
Fulvestrant—Pruritus—Brimonidine—glaucoma	0.000648	0.00118	CcSEcCtD
Fulvestrant—Headache—Bimatoprost—glaucoma	0.000648	0.00118	CcSEcCtD
Fulvestrant—Nervous system disorder—Clonidine—glaucoma	0.000648	0.00118	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—CA1—glaucoma	0.000645	0.00343	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Dorzolamide—glaucoma	0.000645	0.00118	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	0.000643	0.00342	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Travoprost—glaucoma	0.000642	0.00117	CcSEcCtD
Fulvestrant—Skin disorder—Clonidine—glaucoma	0.000641	0.00117	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—EDN1—glaucoma	0.00064	0.0034	CbGpPWpGaD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—MMP2—glaucoma	0.000639	0.00339	CbGpPWpGaD
Fulvestrant—Hyperhidrosis—Clonidine—glaucoma	0.000638	0.00116	CcSEcCtD
Fulvestrant—Nausea—Apraclonidine—glaucoma	0.000634	0.00116	CcSEcCtD
Fulvestrant—Hypersensitivity—Brinzolamide—glaucoma	0.000634	0.00116	CcSEcCtD
Fulvestrant—Vertigo—Betaxolol—glaucoma	0.000633	0.00115	CcSEcCtD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.000632	0.00336	CbGpPWpGaD
Fulvestrant—Dizziness—Acetazolamide—glaucoma	0.000631	0.00115	CcSEcCtD
Fulvestrant—Anorexia—Clonidine—glaucoma	0.00063	0.00115	CcSEcCtD
Fulvestrant—Asthenia—Dorzolamide—glaucoma	0.000628	0.00115	CcSEcCtD
Fulvestrant—ESR1—FOXM1 transcription factor network—MMP2—glaucoma	0.000626	0.00333	CbGpPWpGaD
Fulvestrant—Asthenia—Travoprost—glaucoma	0.000625	0.00114	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—CTSA—glaucoma	0.000625	0.00332	CbGpPWpGaD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—PTGS2—glaucoma	0.000621	0.0033	CbGpPWpGaD
Fulvestrant—Pruritus—Dorzolamide—glaucoma	0.000619	0.00113	CcSEcCtD
Fulvestrant—Asthenia—Brinzolamide—glaucoma	0.000617	0.00113	CcSEcCtD
Fulvestrant—Pruritus—Travoprost—glaucoma	0.000617	0.00112	CcSEcCtD
Fulvestrant—Cough—Betaxolol—glaucoma	0.000615	0.00112	CcSEcCtD
Fulvestrant—Nausea—Bimatoprost—glaucoma	0.000615	0.00112	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—NGF—glaucoma	0.000614	0.00327	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—BCL2L1—glaucoma	0.000614	0.00326	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—NR3C1—glaucoma	0.000611	0.00325	CbGpPWpGaD
Fulvestrant—CYP3A4—Estrogen metabolism—GSTM1—glaucoma	0.000611	0.00325	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Pilocarpine—glaucoma	0.000609	0.00111	CcSEcCtD
Fulvestrant—Pruritus—Brinzolamide—glaucoma	0.000609	0.00111	CcSEcCtD
Fulvestrant—Vomiting—Acetazolamide—glaucoma	0.000607	0.00111	CcSEcCtD
Fulvestrant—Dizziness—Brimonidine—glaucoma	0.000606	0.00111	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Clonidine—glaucoma	0.000602	0.0011	CcSEcCtD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—C3—glaucoma	0.000601	0.00319	CbGpPWpGaD
Fulvestrant—Angiopathy—Timolol—glaucoma	0.0006	0.00109	CcSEcCtD
Fulvestrant—Myalgia—Betaxolol—glaucoma	0.0006	0.00109	CcSEcCtD
Fulvestrant—Arthralgia—Betaxolol—glaucoma	0.0006	0.00109	CcSEcCtD
Fulvestrant—Chest pain—Betaxolol—glaucoma	0.0006	0.00109	CcSEcCtD
Fulvestrant—Diarrhoea—Dorzolamide—glaucoma	0.000599	0.00109	CcSEcCtD
Fulvestrant—Headache—Acetazolamide—glaucoma	0.000598	0.00109	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—NOS3—glaucoma	0.000598	0.00318	CbGpPWpGaD
Fulvestrant—Anxiety—Betaxolol—glaucoma	0.000598	0.00109	CcSEcCtD
Fulvestrant—Insomnia—Clonidine—glaucoma	0.000597	0.00109	CcSEcCtD
Fulvestrant—Immune system disorder—Timolol—glaucoma	0.000597	0.00109	CcSEcCtD
Fulvestrant—Diarrhoea—Travoprost—glaucoma	0.000596	0.00109	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000596	0.00109	CcSEcCtD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—CDKN2B—glaucoma	0.000593	0.00315	CbGpPWpGaD
Fulvestrant—Asthenia—Pilocarpine—glaucoma	0.000593	0.00108	CcSEcCtD
Fulvestrant—Paraesthesia—Clonidine—glaucoma	0.000593	0.00108	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	0.000592	0.00315	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—CA2—glaucoma	0.00059	0.00314	CbGpPWpGaD
Fulvestrant—Dyspnoea—Clonidine—glaucoma	0.000589	0.00107	CcSEcCtD
Fulvestrant—Diarrhoea—Brinzolamide—glaucoma	0.000589	0.00107	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	0.000589	0.00313	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—NR3C1—glaucoma	0.000585	0.00311	CbGpPWpGaD
Fulvestrant—Pruritus—Pilocarpine—glaucoma	0.000585	0.00107	CcSEcCtD
Fulvestrant—Dizziness—Dorzolamide—glaucoma	0.000579	0.00106	CcSEcCtD
Fulvestrant—Rash—Brimonidine—glaucoma	0.000578	0.00105	CcSEcCtD
Fulvestrant—Dermatitis—Brimonidine—glaucoma	0.000577	0.00105	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	0.000577	0.00307	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	0.000577	0.00307	CbGpPWpGaD
Fulvestrant—Dizziness—Travoprost—glaucoma	0.000576	0.00105	CcSEcCtD
Fulvestrant—Malnutrition—Timolol—glaucoma	0.000576	0.00105	CcSEcCtD
Fulvestrant—Headache—Brimonidine—glaucoma	0.000574	0.00105	CcSEcCtD
Fulvestrant—Decreased appetite—Clonidine—glaucoma	0.000574	0.00105	CcSEcCtD
Fulvestrant—ESR1—FOXM1 transcription factor network—CDKN2A—glaucoma	0.000574	0.00305	CbGpPWpGaD
Fulvestrant—Infection—Betaxolol—glaucoma	0.000571	0.00104	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Clonidine—glaucoma	0.00057	0.00104	CcSEcCtD
Fulvestrant—Fatigue—Clonidine—glaucoma	0.000569	0.00104	CcSEcCtD
Fulvestrant—Dizziness—Brinzolamide—glaucoma	0.000569	0.00104	CcSEcCtD
Fulvestrant—Nausea—Acetazolamide—glaucoma	0.000567	0.00103	CcSEcCtD
Fulvestrant—Diarrhoea—Pilocarpine—glaucoma	0.000566	0.00103	CcSEcCtD
Fulvestrant—Pain—Clonidine—glaucoma	0.000565	0.00103	CcSEcCtD
Fulvestrant—Constipation—Clonidine—glaucoma	0.000565	0.00103	CcSEcCtD
Fulvestrant—Nervous system disorder—Betaxolol—glaucoma	0.000564	0.00103	CcSEcCtD
Fulvestrant—Skin disorder—Betaxolol—glaucoma	0.000558	0.00102	CcSEcCtD
Fulvestrant—Vomiting—Dorzolamide—glaucoma	0.000556	0.00102	CcSEcCtD
Fulvestrant—Hyperhidrosis—Betaxolol—glaucoma	0.000556	0.00101	CcSEcCtD
Fulvestrant—Rash—Dorzolamide—glaucoma	0.000552	0.00101	CcSEcCtD
Fulvestrant—Dermatitis—Dorzolamide—glaucoma	0.000551	0.00101	CcSEcCtD
Fulvestrant—Rash—Travoprost—glaucoma	0.000549	0.001	CcSEcCtD
Fulvestrant—Dermatitis—Travoprost—glaucoma	0.000549	0.001	CcSEcCtD
Fulvestrant—Headache—Dorzolamide—glaucoma	0.000548	0.001	CcSEcCtD
Fulvestrant—Anorexia—Betaxolol—glaucoma	0.000548	0.001	CcSEcCtD
Fulvestrant—Vomiting—Brinzolamide—glaucoma	0.000547	0.000998	CcSEcCtD
Fulvestrant—Dizziness—Pilocarpine—glaucoma	0.000547	0.000997	CcSEcCtD
Fulvestrant—Headache—Travoprost—glaucoma	0.000546	0.000996	CcSEcCtD
Fulvestrant—Nausea—Brimonidine—glaucoma	0.000544	0.000993	CcSEcCtD
Fulvestrant—Rash—Brinzolamide—glaucoma	0.000543	0.00099	CcSEcCtD
Fulvestrant—Dermatitis—Brinzolamide—glaucoma	0.000542	0.000989	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Clonidine—glaucoma	0.00054	0.000985	CcSEcCtD
Fulvestrant—Headache—Brinzolamide—glaucoma	0.000539	0.000983	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—MMP1—glaucoma	0.000538	0.00286	CbGpPWpGaD
Fulvestrant—Angioedema—Timolol—glaucoma	0.000526	0.000959	CcSEcCtD
Fulvestrant—Vomiting—Pilocarpine—glaucoma	0.000526	0.000959	CcSEcCtD
Fulvestrant—Urticaria—Clonidine—glaucoma	0.000525	0.000957	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Betaxolol—glaucoma	0.000524	0.000955	CcSEcCtD
Fulvestrant—Body temperature increased—Clonidine—glaucoma	0.000522	0.000952	CcSEcCtD
Fulvestrant—Abdominal pain—Clonidine—glaucoma	0.000522	0.000952	CcSEcCtD
Fulvestrant—Rash—Pilocarpine—glaucoma	0.000521	0.000951	CcSEcCtD
Fulvestrant—Dermatitis—Pilocarpine—glaucoma	0.000521	0.00095	CcSEcCtD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—NR3C1—glaucoma	0.000521	0.00277	CbGpPWpGaD
Fulvestrant—Insomnia—Betaxolol—glaucoma	0.00052	0.000949	CcSEcCtD
Fulvestrant—Nausea—Dorzolamide—glaucoma	0.00052	0.000948	CcSEcCtD
Fulvestrant—Headache—Pilocarpine—glaucoma	0.000518	0.000945	CcSEcCtD
Fulvestrant—Nausea—Travoprost—glaucoma	0.000518	0.000944	CcSEcCtD
Fulvestrant—Vertigo—Timolol—glaucoma	0.000517	0.000943	CcSEcCtD
Fulvestrant—Paraesthesia—Betaxolol—glaucoma	0.000516	0.000942	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—CA1—glaucoma	0.000516	0.00274	CbGpPWpGaD
Fulvestrant—Dyspnoea—Betaxolol—glaucoma	0.000513	0.000935	CcSEcCtD
Fulvestrant—Nausea—Brinzolamide—glaucoma	0.000511	0.000932	CcSEcCtD
Fulvestrant—ESR1—Leptin signaling pathway—BCL2L1—glaucoma	0.000506	0.00269	CbGpPWpGaD
Fulvestrant—Dyspepsia—Betaxolol—glaucoma	0.000506	0.000923	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	0.000504	0.00268	CbGpPWpGaD
Fulvestrant—Cough—Timolol—glaucoma	0.000502	0.000916	CcSEcCtD
Fulvestrant—Decreased appetite—Betaxolol—glaucoma	0.0005	0.000912	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—CTSA—glaucoma	0.0005	0.00266	CbGpPWpGaD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—PTGS2—glaucoma	0.000499	0.00265	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Betaxolol—glaucoma	0.000496	0.000905	CcSEcCtD
Fulvestrant—Fatigue—Betaxolol—glaucoma	0.000496	0.000904	CcSEcCtD
Fulvestrant—Constipation—Betaxolol—glaucoma	0.000492	0.000897	CcSEcCtD
Fulvestrant—Pain—Betaxolol—glaucoma	0.000492	0.000897	CcSEcCtD
Fulvestrant—Nausea—Pilocarpine—glaucoma	0.000491	0.000896	CcSEcCtD
Fulvestrant—Myalgia—Timolol—glaucoma	0.00049	0.000894	CcSEcCtD
Fulvestrant—Arthralgia—Timolol—glaucoma	0.00049	0.000894	CcSEcCtD
Fulvestrant—Chest pain—Timolol—glaucoma	0.00049	0.000894	CcSEcCtD
Fulvestrant—ESR1—FOXA1 transcription factor network—CDKN1B—glaucoma	0.00049	0.0026	CbGpPWpGaD
Fulvestrant—Anxiety—Timolol—glaucoma	0.000488	0.000891	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000487	0.000888	CcSEcCtD
Fulvestrant—Hypersensitivity—Clonidine—glaucoma	0.000487	0.000888	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—MMP9—glaucoma	0.00048	0.00255	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—MMP2—glaucoma	0.000477	0.00254	CbGpPWpGaD
Fulvestrant—Asthenia—Clonidine—glaucoma	0.000474	0.000864	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—CDKN1B—glaucoma	0.000473	0.00251	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CA2—glaucoma	0.000472	0.00251	CbGpPWpGaD
Fulvestrant—Pruritus—Clonidine—glaucoma	0.000467	0.000852	CcSEcCtD
Fulvestrant—Infection—Timolol—glaucoma	0.000467	0.000851	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—CDKN2B—glaucoma	0.000462	0.00246	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—SLC6A1—glaucoma	0.000462	0.00246	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	0.000461	0.00245	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	0.000461	0.00245	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Timolol—glaucoma	0.000461	0.00084	CcSEcCtD
Fulvestrant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.00046	0.00244	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—BAD—glaucoma	0.000459	0.00244	CbGpPWpGaD
Fulvestrant—Urticaria—Betaxolol—glaucoma	0.000457	0.000833	CcSEcCtD
Fulvestrant—Skin disorder—Timolol—glaucoma	0.000456	0.000832	CcSEcCtD
Fulvestrant—Body temperature increased—Betaxolol—glaucoma	0.000455	0.000829	CcSEcCtD
Fulvestrant—Hyperhidrosis—Timolol—glaucoma	0.000454	0.000828	CcSEcCtD
Fulvestrant—Diarrhoea—Clonidine—glaucoma	0.000452	0.000824	CcSEcCtD
Fulvestrant—Anorexia—Timolol—glaucoma	0.000448	0.000817	CcSEcCtD
Fulvestrant—Dizziness—Clonidine—glaucoma	0.000437	0.000797	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	0.000435	0.00231	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	0.000431	0.00229	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Timolol—glaucoma	0.000428	0.000781	CcSEcCtD
Fulvestrant—Insomnia—Timolol—glaucoma	0.000425	0.000775	CcSEcCtD
Fulvestrant—Hypersensitivity—Betaxolol—glaucoma	0.000424	0.000773	CcSEcCtD
Fulvestrant—Paraesthesia—Timolol—glaucoma	0.000422	0.000769	CcSEcCtD
Fulvestrant—Vomiting—Clonidine—glaucoma	0.00042	0.000766	CcSEcCtD
Fulvestrant—Dyspnoea—Timolol—glaucoma	0.000419	0.000764	CcSEcCtD
Fulvestrant—Rash—Clonidine—glaucoma	0.000416	0.00076	CcSEcCtD
Fulvestrant—Dermatitis—Clonidine—glaucoma	0.000416	0.000759	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—TXN—glaucoma	0.000416	0.00221	CbGpPWpGaD
Fulvestrant—Headache—Clonidine—glaucoma	0.000414	0.000755	CcSEcCtD
Fulvestrant—Dyspepsia—Timolol—glaucoma	0.000413	0.000754	CcSEcCtD
Fulvestrant—Asthenia—Betaxolol—glaucoma	0.000413	0.000752	CcSEcCtD
Fulvestrant—Decreased appetite—Timolol—glaucoma	0.000408	0.000745	CcSEcCtD
Fulvestrant—Pruritus—Betaxolol—glaucoma	0.000407	0.000742	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—NR3C1—glaucoma	0.000406	0.00216	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Timolol—glaucoma	0.000406	0.00074	CcSEcCtD
Fulvestrant—Fatigue—Timolol—glaucoma	0.000405	0.000739	CcSEcCtD
Fulvestrant—Pain—Timolol—glaucoma	0.000402	0.000733	CcSEcCtD
Fulvestrant—Diarrhoea—Betaxolol—glaucoma	0.000393	0.000718	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—VEGFA—glaucoma	0.000393	0.00209	CbGpPWpGaD
Fulvestrant—Nausea—Clonidine—glaucoma	0.000392	0.000716	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Timolol—glaucoma	0.000384	0.000701	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—CDKN2A—glaucoma	0.000381	0.00203	CbGpPWpGaD
Fulvestrant—Dizziness—Betaxolol—glaucoma	0.00038	0.000694	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—APOE—glaucoma	0.00038	0.00202	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CA1—glaucoma	0.000377	0.002	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—CAV1—glaucoma	0.000376	0.002	CbGpPWpGaD
Fulvestrant—Urticaria—Timolol—glaucoma	0.000373	0.000681	CcSEcCtD
Fulvestrant—Body temperature increased—Timolol—glaucoma	0.000371	0.000677	CcSEcCtD
Fulvestrant—Abdominal pain—Timolol—glaucoma	0.000371	0.000677	CcSEcCtD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—glaucoma	0.00037	0.00196	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—NOS3—glaucoma	0.000369	0.00196	CbGpPWpGaD
Fulvestrant—Vomiting—Betaxolol—glaucoma	0.000366	0.000667	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—CTSA—glaucoma	0.000365	0.00194	CbGpPWpGaD
Fulvestrant—Rash—Betaxolol—glaucoma	0.000363	0.000661	CcSEcCtD
Fulvestrant—Dermatitis—Betaxolol—glaucoma	0.000362	0.000661	CcSEcCtD
Fulvestrant—CYP3A4—Tryptophan metabolism—CYP1B1—glaucoma	0.000361	0.00192	CbGpPWpGaD
Fulvestrant—Headache—Betaxolol—glaucoma	0.00036	0.000657	CcSEcCtD
Fulvestrant—Hypersensitivity—Timolol—glaucoma	0.000346	0.000631	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—CDKN1B—glaucoma	0.000346	0.00184	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CA2—glaucoma	0.000345	0.00183	CbGpPWpGaD
Fulvestrant—Nausea—Betaxolol—glaucoma	0.000342	0.000623	CcSEcCtD
Fulvestrant—NR1H4—Generic Transcription Pathway—CDKN2B—glaucoma	0.000338	0.0018	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—CDKN1B—glaucoma	0.000338	0.0018	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	0.000337	0.00179	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	0.000337	0.00179	CbGpPWpGaD
Fulvestrant—Asthenia—Timolol—glaucoma	0.000337	0.000615	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—TNF—glaucoma	0.000337	0.00179	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—TXN—glaucoma	0.000333	0.00177	CbGpPWpGaD
Fulvestrant—Pruritus—Timolol—glaucoma	0.000332	0.000606	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	0.000324	0.00172	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—GSTT1—glaucoma	0.000323	0.00171	CbGpPWpGaD
Fulvestrant—Diarrhoea—Timolol—glaucoma	0.000321	0.000586	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	0.000317	0.00168	CbGpPWpGaD
Fulvestrant—ESR1—LKB1 signaling events—TP53—glaucoma	0.000313	0.00167	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—MMP9—glaucoma	0.000313	0.00166	CbGpPWpGaD
Fulvestrant—Dizziness—Timolol—glaucoma	0.000311	0.000567	CcSEcCtD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—APOE—glaucoma	0.000303	0.00161	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—CAV1—glaucoma	0.000301	0.0016	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	0.0003	0.0016	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	0.000299	0.00159	CbGpPWpGaD
Fulvestrant—Vomiting—Timolol—glaucoma	0.000299	0.000545	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	0.000297	0.00158	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—NR3C1—glaucoma	0.000297	0.00158	CbGpPWpGaD
Fulvestrant—Rash—Timolol—glaucoma	0.000296	0.00054	CcSEcCtD
Fulvestrant—Dermatitis—Timolol—glaucoma	0.000296	0.00054	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—CDKN2B—glaucoma	0.000294	0.00156	CbGpPWpGaD
Fulvestrant—Headache—Timolol—glaucoma	0.000294	0.000537	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—VEGFA—glaucoma	0.000293	0.00156	CbGpPWpGaD
Fulvestrant—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.000292	0.00155	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MMP1—glaucoma	0.000291	0.00155	CbGpPWpGaD
Fulvestrant—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.000288	0.00153	CbGpPWpGaD
Fulvestrant—Nausea—Timolol—glaucoma	0.000279	0.000509	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—BAD—glaucoma	0.000262	0.00139	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—BAD—glaucoma	0.000261	0.00139	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	0.00026	0.00138	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—NR3C1—glaucoma	0.000258	0.00137	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—GSTT1—glaucoma	0.000258	0.00137	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—ABCA1—glaucoma	0.000257	0.00137	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—CYP1B1—glaucoma	0.000257	0.00137	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	0.000254	0.00135	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—TNF—glaucoma	0.000251	0.00134	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	0.00025	0.00133	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—TXN—glaucoma	0.000243	0.00129	CbGpPWpGaD
Fulvestrant—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.000237	0.00126	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—CDKN2B—glaucoma	0.000223	0.00118	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—APOE—glaucoma	0.000222	0.00118	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—CAV1—glaucoma	0.00022	0.00117	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	0.000217	0.00115	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—LRP12—glaucoma	0.000215	0.00114	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	0.000214	0.00114	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—TP53—glaucoma	0.000212	0.00113	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	0.000208	0.00111	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CYP1B1—glaucoma	0.000205	0.00109	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—GSTM1—glaucoma	0.000205	0.00109	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—ABCA1—glaucoma	0.000205	0.00109	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—NR3C1—glaucoma	0.000195	0.00104	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	0.000189	0.001	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—GSTT1—glaucoma	0.000188	0.001	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—CDKN1B—glaucoma	0.000182	0.000966	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—MTHFR—glaucoma	0.000182	0.000965	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—APOE—glaucoma	0.000169	0.000898	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—CAV1—glaucoma	0.000167	0.00089	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—GSTM1—glaucoma	0.000164	0.000873	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—CDKN2B—glaucoma	0.000163	0.000865	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	0.00016	0.000849	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—GSTT1—glaucoma	0.000158	0.000838	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	0.000152	0.000808	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—VEGFA—glaucoma	0.000152	0.000807	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	0.000151	0.000804	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—ABCA1—glaucoma	0.00015	0.000798	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CYP1B1—glaucoma	0.00015	0.000798	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—OPN4—glaucoma	0.000149	0.000792	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—CDKN2B—glaucoma	0.000148	0.000789	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—MTHFR—glaucoma	0.000145	0.000771	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—NR3C1—glaucoma	0.000143	0.000759	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—CDKN2B—glaucoma	0.000142	0.000753	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HEYL—glaucoma	0.000138	0.000736	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—APOE—glaucoma	0.000135	0.000718	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PTGFR—glaucoma	0.000134	0.000713	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CAV1—glaucoma	0.000134	0.000712	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—NR3C1—glaucoma	0.00013	0.000692	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—NOS3—glaucoma	0.000127	0.000673	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	0.000126	0.000669	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—CYP1B1—glaucoma	0.000126	0.000668	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—NR3C1—glaucoma	0.000124	0.000661	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—CYP1B1—glaucoma	0.000124	0.000659	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—GSTM1—glaucoma	0.00012	0.000638	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PTGS2—glaucoma	0.000116	0.000616	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—TP53—glaucoma	0.000115	0.00061	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CA5A—glaucoma	0.000111	0.000588	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NARFL—glaucoma	0.000111	0.000588	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	0.000108	0.000573	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—MTHFR—glaucoma	0.000106	0.000564	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—RPTOR—glaucoma	0.000105	0.000558	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NCK2—glaucoma	0.000102	0.00054	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—NOS3—glaucoma	0.000101	0.000538	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—GSTM1—glaucoma	0.0001	0.000534	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—GSTM1—glaucoma	9.91e-05	0.000527	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—APOE—glaucoma	9.87e-05	0.000525	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CAV1—glaucoma	9.78e-05	0.00052	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	9.51e-05	0.000505	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PTGS2—glaucoma	9.26e-05	0.000492	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HDAC9—glaucoma	8.64e-05	0.000459	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—NOS3—glaucoma	7.4e-05	0.000393	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—CDKN2B—glaucoma	7.15e-05	0.00038	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PTGS2—glaucoma	6.77e-05	0.00036	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SMO—glaucoma	6.76e-05	0.000359	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—NR3C1—glaucoma	6.27e-05	0.000333	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NTRK2—glaucoma	6.18e-05	0.000329	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CA1—glaucoma	5.4e-05	0.000287	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NGFR—glaucoma	5.31e-05	0.000282	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CTSA—glaucoma	5.23e-05	0.000278	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NTRK1—glaucoma	5.04e-05	0.000268	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CA2—glaucoma	4.94e-05	0.000262	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CDKN2B—glaucoma	4.65e-05	0.000247	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—EDN1—glaucoma	4.46e-05	0.000237	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NGF—glaucoma	4.1e-05	0.000218	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—C3—glaucoma	3.89e-05	0.000207	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—APOE—glaucoma	3.63e-05	0.000193	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CAV1—glaucoma	3.59e-05	0.000191	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—TXN—glaucoma	3.48e-05	0.000185	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FN1—glaucoma	3.42e-05	0.000182	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—BAD—glaucoma	3.38e-05	0.00018	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NOS3—glaucoma	2.72e-05	0.000144	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTT1—glaucoma	2.7e-05	0.000143	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CDKN1B—glaucoma	2.35e-05	0.000125	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MMP9—glaucoma	2.18e-05	0.000116	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ABCA1—glaucoma	2.15e-05	0.000114	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CYP1B1—glaucoma	2.15e-05	0.000114	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—VEGFA—glaucoma	1.96e-05	0.000104	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTM1—glaucoma	1.72e-05	9.13e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—MTHFR—glaucoma	1.52e-05	8.07e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TP53—glaucoma	1.48e-05	7.86e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—APOE—glaucoma	1.41e-05	7.51e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CAV1—glaucoma	1.4e-05	7.44e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NOS3—glaucoma	1.06e-05	5.63e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PTGS2—glaucoma	9.68e-06	5.15e-05	CbGpPWpGaD
